LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced the release of four abstracts on its drug candidate PB272 (neratinib) that will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 29 to June 2, 2015, in Chicago. Abstracts are available to the public online on the ASCO website: www.abstract.asco.org:
Abstract #508: Breast Cancer—HER2/ER, Oral Abstract Session
Abstract #610: Breast Cancer—HER2/ER, Poster Session
Abstract #1085: Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy, Poster Session
Abstract #1099: Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy, Poster Session
Help employers find you! Check out all the jobs and post your resume.
Abstract #508: Breast Cancer—HER2/ER, Oral Abstract Session
Abstract #610: Breast Cancer—HER2/ER, Poster Session
Abstract #1085: Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy, Poster Session
Abstract #1099: Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy, Poster Session
Help employers find you! Check out all the jobs and post your resume.
